Utilization of fluoroquinolones and Escherichia coli resistance in urinary tract infection: Inpatients and outpatients

Pharmacoepidemiology and Drug Safety

Volumn 14, Issue 10, 2005, Pages 741-745

  Urbánek, Karel ^a   Kolář, Milan ^a   Strojil, Jan ^a   Koukalová, Dagmar ^a   Čekanová, Luboslava ^a   Hejnar, Petr ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Czech Republic; Drug utilization; Escherichia coli; Fluoroquinolones; Resistance

Indexed keywords

QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; CORRELATION ANALYSIS; CZECH REPUBLIC; DRUG USE; ESCHERICHIA COLI; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; OUTPATIENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; URINARY TRACT INFECTION;

EID: 27144554197     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.1110     Document Type: Article

References (17)

1. Jones RN, Baquero F, Privitera G, Inoue M, Wiedemann B. Inducible β-lactamase mediated resistance to third-generation cephalosporins. Clin Microbiol Infect 1997; 3: 7-20.
2. Neu HC. The crisis of antibiotic resistance. Science 1992; 257: 1064-1072.
3. Vila J, Ruiz J, Marco FBA, et al. Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs. Antimicrob Agents Chemother 1994; 38: 2477-2479.
4. Vila J, Ruiz J, Goñi P, Jimenez de Anta MT. Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli. Antimicrob Agents Chemother 1996; 40: 491-493.
5. Weigel LM, Anderson GJ, Tenover FC. DNA gyrase and topoisomerase IV mutations associated with fluoroquinolone resistance in Proteus mirabilis. Antimicrob Agents Chemother 2002; 46: 2582-2587.
6. Aguiar JM, Chacon J, Canton R, Baquero F. The emergence of highly fluoroquinolone-resistant E. coli in community-acquired urinary tract infections. J Antimicrob Chemother 1992; 29: 349-350.
7. Garau J, Xercavins M, Rodríguez-Carballeira M, et al. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother 1999; 43: 2736-2741.
8. Peña C, Pallarés R, Pujol M, Tubau F, Ariza J. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli. Antimicrob Agents Chemother 1995; 39: 520-524.
9. Lautenbach E, Strom BL, Nachamkin I, et al. Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, 1989-2000: differences in the emergence and epidemiology of resistance across organisms. Clin Infect Dis 2004; 38: 655-662.
10. Lautenbach E, Strom BL, Bilker WB, et al. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 2001; 33: 1288-1294.
11. McDonald LC, Chen FJ, Lo HJ, et al. Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia coli in Taiwan and contributions of distinct selective pressures. Antimicrob Agents Chemother 2001; 45: 3084-3091.
12. Anatomical therapeutic chemical (ATC). Index (including defined daily doses (DDDs) for plain substances). WHO collaboration centre for drugs statistics methodology, Oslo, 2002.
13. NCCLS. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. M7-A5. National Committee for Clinical Laboratory Standards, 2000, Wayne Pa.
14. Peña C, Albareda JM, Pallarés R, et al. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in blood-stream infections. Antimicrob Agents Chemother 1995; 39: 520-524.
15. Kolár̂ M, Urbánek K, Látal T. Antibiotic selection pressure and development of bacterial resistance. Intern J Antimicrob Agents 2001; 17: 357-363.
16. Do antimicrobial control programmes have a positive effect on patient outcomes? Drug Ther Perspect 2004; 20: 22-24.
17. Bolon MK, Wright SB, Gold HS, Carmeli Y. The magnitude of the association between fluofoquinolone use and quinolone-resistant Escherichia coli and Klebsiella pneumoniae may be lower than previously reported. Antimicrob Agents Chemother 2004; 48: 1934-1940.